MX2018007147A - Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion. - Google Patents

Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion.

Info

Publication number
MX2018007147A
MX2018007147A MX2018007147A MX2018007147A MX2018007147A MX 2018007147 A MX2018007147 A MX 2018007147A MX 2018007147 A MX2018007147 A MX 2018007147A MX 2018007147 A MX2018007147 A MX 2018007147A MX 2018007147 A MX2018007147 A MX 2018007147A
Authority
MX
Mexico
Prior art keywords
preventing
cognitive impairment
neuroinflammation
treating aging
associated cognitive
Prior art date
Application number
MX2018007147A
Other languages
English (en)
Inventor
Dinh Nguyen Khoa
G Engleman Edgar
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2018007147A publication Critical patent/MX2018007147A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se relaciona con un método para prevenir y/o tratar el deterioro cognitivo relacionado con el envejecimiento en el sistema nervioso central. El método comprende administrar a un paciente que lo necesita un activador de Ppargc1a 2-(4-terc-butilfenil)-1H-bencimidazol, 2-[4-(1,1-dimetiletil)fenil]-1H-bencimidazol, en una cantidad efectiva. Una ruta de administración preferida es la administración oral.
MX2018007147A 2015-12-15 2016-12-09 Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion. MX2018007147A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267437P 2015-12-15 2015-12-15
PCT/US2016/065972 WO2017106050A1 (en) 2015-12-15 2016-12-09 Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

Publications (1)

Publication Number Publication Date
MX2018007147A true MX2018007147A (es) 2019-03-28

Family

ID=59057428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007147A MX2018007147A (es) 2015-12-15 2016-12-09 Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion.

Country Status (18)

Country Link
US (3) US10653669B2 (es)
EP (2) EP3390367B1 (es)
JP (1) JP6837486B2 (es)
KR (1) KR20180094989A (es)
CN (1) CN108884053B (es)
AU (1) AU2016371598B2 (es)
CA (1) CA3008019A1 (es)
DK (1) DK3390367T3 (es)
ES (1) ES2830447T3 (es)
HK (1) HK1261918A1 (es)
HR (1) HRP20201652T1 (es)
HU (1) HUE051771T2 (es)
IL (2) IL259902B (es)
MX (1) MX2018007147A (es)
PL (1) PL3390367T3 (es)
PT (1) PT3390367T (es)
RS (1) RS61053B1 (es)
WO (1) WO2017106050A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3000985C (en) 2014-10-14 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
TW202019410A (zh) * 2018-08-06 2020-06-01 小利蘭史丹佛大學董事會 作為用於治療神經退化性疾病的ppargc1a活化劑的2-芳基苯并咪唑
US20240316008A1 (en) 2020-06-22 2024-09-26 Tranquis Therapeutics, Inc. Treatment of systemic immune activation syndromes
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
US20240307356A1 (en) * 2021-06-17 2024-09-19 Tranquis Therapeutics, Inc. Therapeutically effective oral administration of a 2 arylbenzimidazole
EP4426295A1 (en) 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
TW202415372A (zh) 2022-06-14 2024-04-16 美商特朗奎斯治療股份有限公司 老化相關改變及疾病之治療
TW202416960A (zh) 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
WO2024105635A1 (en) * 2022-11-18 2024-05-23 Kyoto Prefectural University Of Medicine Uses of zln-005 and related compounds
WO2024118936A1 (en) 2022-12-02 2024-06-06 Tranquis Therapeutics, Inc. 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53127475A (en) * 1977-04-07 1978-11-07 Kanebo Ltd Novel benzimidazole compound and its preparation
GB1584296A (en) 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
NZ222495A (en) 1986-11-21 1991-04-26 Haessle Ab Benzimidazole derivatives and pharmaceutical compositions
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
CZ20011546A3 (cs) 1998-11-03 2001-08-15 Basf Aktiengesellschaft Derivát substituovaného 2-fenylbenzimidazolu, způsob jeho přípravy a jeho použití
SI1246808T1 (sl) * 2000-01-14 2011-12-30 Bayer Pharma AG 1-2 - diarilni benzimidazoli za zdravljenje bolezni povezanih z aktivacijo mikroglije
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
US20040002524A1 (en) * 2002-06-24 2004-01-01 Richard Chesworth Benzimidazole compounds and their use as estrogen agonists/antagonists
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
CN1968948A (zh) 2004-06-17 2007-05-23 惠氏公司 用于制备促性腺激素释放激素受体拮抗剂的方法
KR20070057965A (ko) * 2004-09-21 2007-06-07 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
US7689227B2 (en) * 2005-03-02 2010-03-30 Qualcomm Incorporated Method and apparatus for hashing over multiple frequency bands in a communication system
JP5066514B2 (ja) * 2005-03-14 2012-11-07 ハイ ポイント ファーマシューティカルズ，エルエルシー ベンズアゾール誘導体、組成物及びβ−セクレターゼ阻害剤としての使用方法
ES2396913T3 (es) 2005-08-04 2013-03-01 Sirtris Pharmaceuticals, Inc. Compuestos moduladores de sirtuina
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
GB201009656D0 (en) 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
AU2013250726B2 (en) 2012-04-20 2017-01-05 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
WO2014179303A1 (en) * 2013-04-29 2014-11-06 The General Hospital Corporation Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease
JP6483711B2 (ja) * 2013-09-18 2019-03-13 ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ フェノフィブラート及びその類似体を用いた神経変性疾患の治療
CA3000985C (en) 2014-10-14 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CN104873500A (zh) * 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
JP7134089B2 (ja) * 2015-05-18 2022-09-09 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化に関連した障害を処置するための方法及び組成物

Also Published As

Publication number Publication date
JP2018537507A (ja) 2018-12-20
CN108884053B (zh) 2022-01-04
CA3008019A1 (en) 2017-06-22
HRP20201652T1 (hr) 2020-12-25
US20240245646A1 (en) 2024-07-25
WO2017106050A1 (en) 2017-06-22
ES2830447T3 (es) 2021-06-03
AU2016371598B2 (en) 2021-05-13
EP3390367B1 (en) 2020-09-09
IL285248A (en) 2021-09-30
BR112018012195A2 (pt) 2018-12-18
US10653669B2 (en) 2020-05-19
HUE051771T2 (hu) 2021-03-29
US20210059985A1 (en) 2021-03-04
IL259902A (en) 2018-07-31
DK3390367T3 (da) 2020-10-26
JP6837486B2 (ja) 2021-03-03
KR20180094989A (ko) 2018-08-24
PT3390367T (pt) 2020-09-23
EP3390367A4 (en) 2019-08-07
PL3390367T3 (pl) 2021-03-08
CN108884053A (zh) 2018-11-23
EP3390367A1 (en) 2018-10-24
HK1261918A1 (zh) 2020-01-10
AU2016371598A1 (en) 2018-07-12
US20180353474A1 (en) 2018-12-13
IL259902B (en) 2021-08-31
EP3741747A1 (en) 2020-11-25
EP3741747B1 (en) 2024-10-16
RS61053B1 (sr) 2020-12-31

Similar Documents

Publication Publication Date Title
MX2018007147A (es) Metodo para prevenir y/o tratar el daño cognitivo asociado al envejecimiento y la neuroinflamacion.
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
PH12017501046A1 (en) Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
SG10201907819WA (en) N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors,
GEP20207159B (en) Diacylglycerol acyltransferase 2 inhibitors
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
MA54252A (fr) Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
MX367918B (es) Compuestos heterociclicos fusionados como inhibidores de proteina quinasa.
EA201790271A1 (ru) Ингибиторы гликозидазы
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
CL2021000044A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia (divisional solicitud no. 1376-2017)
EA201890256A1 (ru) 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MD3319967T2 (ro) Compuşi inhibitori ai căii de semnalizare Notch
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MA48942A (fr) Composés thérapeutiques, compositions et procédés d'utilisation associés
MX368518B (es) Prevencion y remocion de manchas dentales.
CY1125031T1 (el) Μεθοδος για γενετικη θεραπεια χρησιμοποιωντας τον ιο aav-xbp1s/gfp και χρηση αυτης στην προληψη και τη θεραπεια της αμυοτροφικης πλευρικης σκληρυνσης
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
MX2017007955A (es) Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas.
EP4249072A3 (en) Crystalline forms of quinolone analogs and their salts